Skip to main content

Congress Materials

Search by MeetingSearch by Disease Area
FILTER
Filter events:
12th Annual University of California, Irvine (UCI) Neuromuscular Colloquium 2024
American Academy of Dermatology (AAD), 2024
American Academy of Neurology (AAN), 2024
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2023
American College of Rheumatology (ACR), 2023
Congress of Clinical Dermatology (CCD), 2024
Congress of Clinical Rheumatology (CCR) East, 2024 
Congress of Clinical Rheumatology (CCR) West, 2023
European Academy of Dermatology & Venereology (EADV), 2023
European Alliance of Associations for Rheumatology (EULAR), 2024
European Hidradenitis Suppurativa Foundation (EHSF), 2024
Fall Clinical Dermatology, 2023
Fall Clinical PA + NP, 2024 
International Federation of Psoriasis Associations (IFPA), 2024
Masterclass in Dermatology, 2024
Maui Derm Hawaii, 2024
Maui Derm NP + PA Fall, 2023
Maui Derm PA + NP Summer, 2024 
Muscular Dystrophy Association (MDA), 2024
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2023
RheumNow Live! (RNL), 2024
Society for Investigative Dermatology (SID), 2024
Society of Dermatology Physician Assistants (SDPA) Fall, 2023
Society of Dermatology Physician Assistants (SDPA) Summer, 2024 
State of Texas Association of Rheumatologists (STAR), 2024
United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine Conference, 2024
Winter Clinical Hawaii, 2024
Winter Clinical Miami, 2024
World Congress of Dermatology, 2023
FILTER
Select topic(s):
Content type:
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
et al.
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
et al.
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
et al.
Association of EQ VAS with treatment benefits and patient-reported benefits in patients with moderate to severe psoriasis – data from the German national psoriasis registry PsoBest
et al.
Association of Hidradenitis Suppurativa Flares and the Menstrual Cycle: A Prospective Cohort Study
et al.
Association of Hidradenitis Suppurativa Flares and the Menstrual Cycle: A Prospective Cohort Study
et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
et al.
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
et al.
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
et al.
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
et al.
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
et al.
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
et al.
Bimekizumab and secukinumab comparative effectiveness in hidradenitis suppurativa: Indirect treatment comparisons at Week 16 and 1 Year
et al.
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
et al.
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
et al.
Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
et al.
Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-Week results from the Phase 3 active reference study BE OPTIMAL
et al.
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
et al.
Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3 year results from BE BRIGHT, a multicenter, open label, phase 3 study
et al.
Bimekizumab Efficacy and Safety in Patients with Active Psoriatic Arthritis and Psoriasis: 52-Week Results from the BE OPTIMAL and BE COMPLETE Phase 3 Randomised, Placebo-Controlled Studies
et al.
Bimekizumab efficacy and safety in patients with psoriatic arthritis and psoriasis: Up to 2-year results from two phase 3 studies
et al.
Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
et al.
Bimekizumab efficacy by body region in plaque psoriasis: Comparative analyses from four phase 3/3b studies
et al.
Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II
et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
et al.
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
et al.
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in fatigue observed in two phase 3 studies
et al.
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE
et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index, or hyperglycemia: Results through 3 years of treatment in 5 phase 3/3b trials
et al.
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
et al.
Bimekizumab efficacy through 144 weeks in moderate to severe plaque psoriasis: Patient-reported outcomes from BE RADIANT
et al.
Bimekizumab efficacy through 3 years in patients with moderate to severe plaque psoriasis: Long-term pooled analysis from BE BRIGHT
et al.
Bimekizumab efficacy through Year 1 in patients with moderate to severe plaque psoriasis who had not achieved a PASI 90 response by Week 16: A pooled analysis from four phase 3/3b trials
et al.
Bimekizumab impact on cardiovascular inflammation markers in moderate to severe plaque psoriasis: Results from phase 3 trials
et al.
Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II
et al.
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
et al.
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
et al.
Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II
et al.
Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II
et al.
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis who were Biologic DMARD-Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized
et al.
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
et al.
Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II
et al.
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
et al.
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
et al.
Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis
et al.
Bimekizumab improves key patient-reported symptoms of axial spondyloarthritis including spinal pain and fatigue: Results from two phase 3 studies
et al.
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
et al.
Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48
et al.
Bimekizumab in patients with moderate to severe plaque psoriasis: Analysis of mental health and associated disorders
et al.
Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Mean percentage improvement in clinical outcomes over 4 years
et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis who were Responders at Week 16: Results from a Phase 3, Active Reference Study
et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies
et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study
et al.
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-αα Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study
et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
et al.
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
et al.
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
et al.
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
et al.
Bimekizumab reduced psoriatic arthritis impact in patients with psoriasis: Up to 2-year results from two phase 3 studies
et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
et al.
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
et al.
Bimekizumab response through 3 years in patients with plaque psoriasis who stopped and re-started treatment
et al.
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
et al.
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
et al.
Bimekizumab Safety in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Rates of Hepatic Events and Transaminase Elevations in Phase 3 Trials
et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
et al.
Bimekizumab simultaneous skin and nail clearance in patients with psoriasis: Assessing comparative efficacy in four phase 3/3b studies
et al.
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
et al.
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
et al.
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
et al.
Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD-Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
et al.
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
et al.
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and its Open-Label Extension up to 1 Year
et al.
Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response
et al.
Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
et al.
Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
et al.
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
et al.
Bimekizumab versus secukinumab continuous maintenance of PASI 90 and PASI 100 responses through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
et al.
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
et al.
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
et al.
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies
et al.
Characteristics, Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States
et al.
Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-Hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study
et al.
Corticosteroid dose tapering in patients with generalized myasthenia gravis on zilucoplan: Interim analysis of RAISE-XT
et al.
Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-Label Extension Studies
et al.
Durability of response among patients with psoriatic arthritis (PsA) using biological or targeted synthetic disease-modifying antirheumatic drugs in the CorEvitas PsA/spondyloarthritis registry
et al.
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
et al.
Early responders with zilucoplan: An interim analysis of RAISE-XT in patients with generalized myasthenia gravis
et al.
Effect of zilucoplan on disease fluctuation in patients with generalized myasthenia gravis in the Phase 3 RAISE study
et al.
Effect of zilucoplan on fatigue in generalized myasthenia gravis in the Phase 3 RAISE and RAISE-XT studies
et al.
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
et al.
Efficacy of repeated cycles of rozanolixizumab treatment in subgroups of patients with generalized myasthenia gravis: A pooled analysis of a Phase 3 study and two Phase 3 open-label extension studies
et al.
Harnessing New Potential in Generalized Myasthenia Gravis (gMG): When Individuality Meets Optionality
et al.
IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials
et al.
Impact of Bimekizumab on MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from the BE MOBILE 1 and 2 Phase 3 Studies
et al.
Interactions of Fcy receptors with an IgG4 format, anti-FcRn monoclonal antibody, rozanolixizumab
et al.
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
et al.
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension
et al.
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
et al.
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension
et al.
Long-Term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT
et al.
Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
et al.
Long-term safety of repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis
et al.
Long-term safety of repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis
et al.
Long-Term Sustained Efficacy and Safety of Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
et al.
Looking beyond the numbers: Interpreting patient experience of rozanolixizumab in generalized myasthenia gravis from the MycarinG clinical trial
et al.
Management and treatment patterns in psoriasis and psoriatic arthritis
et al.
MG-ADL and QMG scores over time in patients with generalized myasthenia gravis: Post-hoc analysis of MycarinG and open-label studies
et al.
Mitochondrial Myopathies Mimicking Neuromuscular Diseases: A Case-Based Exploration
et al.
Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment
et al.
Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa
et al.
Patient experiences of thymidine kinase 2 deficiency (TK2d): preliminary results from an online survey conducted in partnership with the patient community
et al.
Patient Preferences for Myasthenia Gravis Treatments: A Discrete-Choice Experiment
et al.
Patient-reported outcomes during repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis in the Phase 3 MycarinG and open-label extension studies
et al.
Patients with psoriatic arthritis at biologic therapy switch: The CorEvitas psoriasis registry
et al.
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
et al.
Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label, Phase 1b CHERISH Study
et al.
Purified monoclonal rheumatoid factors bind to Fc containing TNF inhibitors in vitro but not to the Fc-free TNF inhibitor, certolizumab pegol
et al.
Rapid, Sustained Improvements in Routine Assessment of Patient Index Data 3 in Bimekizumab-Treated Patients With Psoriatic Arthritis: Post-Hoc Analysis of Two Phase 3 Studies
et al.
Real world data on the 1-year treatment of psoriasis with the use of certolizumab pegol in women of child-bearing potential
et al.
Real-world data on the use of certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 1-year results from a prospective non-interventional cohort study
et al.
Real-world patient characteristics and prior treatment history of bimekizumab patients in Germany
et al.
Repeated cycles of rozanolixizumab treatment in patients with muscle-specific kinase autoantibody-positive generalized myasthenia gravis
et al.
Repeated cycles of rozanolixizumab treatment in patients with muscle-specific kinase autoantibody-positive generalized myasthenia gravis
et al.
Reporting mental health and associated disorders from trials of bimekizumab in patients with active axial spondyloarthritis and psoriatic arthritis
et al.
Response rates with zilucoplan among generalized myasthenia gravis patients in an interim analysis of RAISE-XT, a Phase 3 open-label extension study
et al.
Response rates with zilucoplan among patients with generalized myasthenia gravis in an interim analysis of RAISE-XT, a Phase 3 open-label extension study
et al.
Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis
et al.
Rheumatology Care Journey Among Patients with Psoriatic Arthritis or Axial Spondyloarthritis in the United States
et al.
Risk of myasthenia gravis exacerbation and level of healthcare resource utilization by Myasthenia Gravis Activities of Daily Living score
et al.
Safety, Efficacy, and Patient Preference for Subcutaneous Zilucoplan in Myasthenia Gravis After Switching from Intravenous Complement 5 Component 5 Inhibitors: An Interim Analysis of a Phase 3b Study
et al.
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
et al.
Social determinants of health are associated with suboptimal treatment among individuals with myasthenia gravis
et al.
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
et al.
Subcutaneous rozanolixizumab in pediatric patients with generalized myasthenia gravis: Clinical study design
et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE Study and its open-label extension up to 1 year
et al.
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
et al.
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
et al.
Temporal impact of infection-related treatment emergent adverse events on patient-reported outcomes in patients with moderate to severe psoriasis – analysis of the German national registry PsoBest
et al.
The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004)
et al.
Time to Diagnosis and Associated Comorbidity Burden in Axial Spondyloarthritis in General Practice in France: Results from the THIN® Database
et al.
Treatment history and symptom severity in patients with moderate to severe plaque psoriasis being initiated on bimekizumab: Use during the 1st year of routine clinical practice
et al.
Understanding the Role of the IL-17 Cytokine Family in Health and Disease
et al.
Utilizing Patient-Reported Data to Improve Understanding of Flare Predictors in Patients with Moderate to Severe Hidradenitis Suppurativa
et al.
Watch Video: Clinical Relevance of High Rheumatoid Factor in Patients with Rheumatoid Arthritis
et al.
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment Over 52 Weeks: Results from Two Phase 3 Studies
et al.
Zilucoplan in pediatric patients with acetylcholine receptor autoantibody positive generalized myasthenia gravis: ziMyG (MG0014) and ziMyG + (MG0015) clinical study designs
et al.